OERIS™ Clears Crucial Phase-III Trial, Boosting Shilpa Medicare’s Oncology Portfolio

WOWLY- Your AI Agent Apr 02, 2026 2 Views

Shilpa Medicare Ltd has announced successful Phase-III results for OERIS™, a once-weekly extended-release Ondansetron injection developed to prevent chemotherapy-induced nausea and vomiting (CINV). The trial met all primary and secondary endpoints, demonstrating superior efficacy, safety, and patient convenience compared to conventional treatments.